Abstracts tagged "belimumab and systemic lupus erythematosus (SLE)"

Abstract Number: 742 • 2016 ACR/ARHP Annual Meeting
A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea
Fengchun Zhang¹, Sang-Cheol Bae², Damon Bass³, Myron Chu³, Sally Egginton⁴, David Gordon³, David Roth³, Yoshiya Tanaka⁵ and Jie Zheng⁶, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³GSK, Philadelphia, PA, ⁴GSK, Stevenage, United Kingdom, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ⁶Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: SLE is an autoimmune disease associated with elevated levels of B Lymphocyte Stimulator (BLyS). This study assessed the efficacy and safety of belimumab (BLyS-specific…
Abstract Number: 775 • 2016 ACR/ARHP Annual Meeting
Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Alejandra Babini¹, Mercedes Argentina García², Juan Carlos Barreira³, Bernado Pons-Estel⁴, Melitza Iglesias⁵ and Gabriela Streger⁶, ¹Hospital Italiano de Cordoba, Cordoba, Argentina, ²Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ³Hospital Britanico, Buenos Aires, Argentina, ⁴Sanatorio Parque, Rosario, Argentina, ⁵Medical Affairs, GlaxoSimthKline, Philadelphia, PA, ⁶Direccion Medica, GlaxoSmithKline, Buenos Aires, Argentina
Background/Purpose: Studying clinical effectiveness of belimumab treatment in real world clinical practice of Systemic Lupus Erythematosus (SLE) is relevant in assessing external validity of randomized…
Abstract Number: 1113 • 2015 ACR/ARHP Annual Meeting
B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
Michelle T. Ngo¹, Abigail Benitez², Kimberly J. Payne², Michael De Vera³, Terry Ann Milford² and Karina Marianne D. Torralba⁴, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA
Background/Purpose: The B cell pool is composed of subsets with different phenotypes and functions that mainly have effector functions to maintain immunologic tolerance. These…
Abstract Number: 760 • 2015 ACR/ARHP Annual Meeting
Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)
Andreas Schwarting¹, Mary Anne Dooley², David Roth³, Lisa Edwards⁴, April Thompson⁴ and Barbara Wilson⁴, ¹ACURA Kliniken, Bad Kreuznach, Germany, ²University of North Carolina, Chapel Hill, NC, ³GlaxoSmithKline, King of Prussia, PA, ⁴GlaxoSmithKline, Chapel Hill, NC
Background/Purpose: Belimumab is licensed as add-on therapy to standard lupus care (SoC) in patients with active SLE. Physicians have inquired about the efficacy and safety…
Abstract Number: 735 • 2015 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Luca Iaccarino¹, Silvano Bettio¹, Rossella Reggia², Margherita Zen³, Micol Frassi², Laura Andreoli², Linda Nalotto¹, Mariele Gatto¹, Lara Pea², Nicola Bassi¹, Maddalena Larosa¹, Alessandra Zanola², Leonardo Punzi⁴, Angela Tincani² and Andrea Doria¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Division of Rheumatology, University of Padova, Padova, Italy, ⁴Unit of Rheumatology, University of Padova, Padova, Italy
Background/Purpose: To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy. Methods: Fifty-eight patients,…
Abstract Number: 671 • 2014 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting
Andrea Doria¹, Luca Iaccarino², Silvano Bettio², Micol Frassi³, Laura Andreoli³, Rossella Reggia³, Margherita Zen², Linda Nalotto², Mariele Gatto², Lara Pea³, Leonardo Punzi¹ and Angela Tincani³, ¹Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Department of Medicine-DIMED, University of Padova, Padova, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical…
Abstract Number: 614 • 2012 ACR/ARHP Annual Meeting
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Roger A. Levy³, Sandra V. Navarra⁴, Jill P. Buyon⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Ricard Cervera⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Internal Medicine, Univ Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Predicting which SLE patients are at increased risk for clinically meaningful flares may be useful in making management decisions. The purpose of this analysis was to…
Abstract Number: 2246 • 2012 ACR/ARHP Annual Meeting
Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study
Susan S. Kim¹, Tanya Pavri¹, Kyriakos A. Kirou², Jane Salmon¹ and Doruk Erkan¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: With the recent FDA approval of belimumab, clinicians are faced with adjusting their SLE treatment paradigm. The purpose of this study was to examine…
Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting
Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients
Joan T. Merrill¹, Richard A. Furie², Daniel J. Wallace³, William Stohl⁴, W. Winn Chatham⁵, Arthur Weinstein⁶, James D. McKay, Ellen M. Ginzler⁸, Z. John Zhong⁹, William W. Freimuth⁹ and Michelle Petri¹⁰, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²North Shore-LIJ Health System, Lake Success, NY, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Washington Hospital Center, Washington, DC, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ⁸Human Genome Sciences, Inc., Rockville, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE. Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…